In this context, the synergistic effect of combined use of alum and monophosphoryl lipid A (MPL as a TLR4 agonist) for a multi-type HPV L2 fusion peptide21, and also TLR7 agonist either as external adjuvant (AS37) for a subunit SARS-CoV-2 vaccine23 or as a built-in adjuvant for an anti-tumor vaccine22 to enhance the immune responses have been shown. The gene discussed is TLR7; the disease is neoplasm.